In a preclinical study published in the Journal of Controlled Release, Harvard Medical School researchers investigated the kinetics of blood-brain barrier permeability and drug delivery following single and double focused ultrasound sonications. They found that delivery of the chemotherapy agent, doxorubicin, was significantly greater when one focused ultrasound sonication was used and 1.5-fold higher when a second sonication was administered ten minutes later. Study data suggests that MRI contrast agent Gd-DTPA may be useful as a surrogate tracer in estimating drug delivery to the brain following focused ultrasound-induced blood-brain barrier disruption.

 

Lead author of the study is Juyoung Park, PhD, a research fellow in radiology at Brigham and Women's Hospital and Harvard Medical School. Co-authors are Yongzhi Zhang, MD; Natalia Vykhodtseva, PhD; Ferenc A. Jolesz, MD; and Nathan J. McDannold, PhD.

Read abstract

The Focused Ultrasound Foundation Newsletter

Our newsletter delivers updates for clinicians, researchers and patients. Sign up and stay on top of the rapid advancements of this innovative medical technology.

Sign Up  Read the Latest Issue

Read The Tumor  by John Grisham

From John Grisham, comes a story where today’s medical fiction could become tomorrow’s lifesaving reality.

Download a Free eBook or Audiobook

Contact Details

Call Us
434.220.4993
Find Us
Focused Ultrasound Foundation
1230 Cedars Court, Suite 206 Charlottesville, VA 22903
Email